We are live on ! Find out more
XERS icon

Xeris Biopharma Holdings

50 hedge funds and large institutions have $193M invested in Xeris Biopharma Holdings in 2019 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 21 increasing their positions, 8 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

163% more repeat investments, than reductions

Existing positions increased: 21 | Existing positions reduced: 8

30% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 10

20% more capital invested

Capital invested by funds: $161M → $193M (+$32.2M)

3.17% more ownership

Funds ownership: 59.43%62.6% (+3.2%)

2% more funds holding

Funds holding: 4950 (+1)

Holders
50
Holders Change
+1
Holders Change %
+2.04%
% of All Funds
1.09%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
13
Increased
21
Reduced
8
Closed
10
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Millennium Management
51
Millennium Management
New York
-$1.21M -120,750 Closed
MIM
52
Monashee Investment Management
Massachusetts
-$1M -100,000 Closed
Two Sigma Investments
53
Two Sigma Investments
New York
-$753K -75,022 Closed
EGM
54
Engineers Gate Manager
New York
-$425K -42,333 Closed
PCM
55
Pentwater Capital Management
Florida
-$402K -40,000 Closed
Citadel Advisors
56
Citadel Advisors
Florida
-$301K -29,941 Closed
CSS
57
Cubist Systematic Strategies
Connecticut
-$258K -25,693 Closed
Marshall Wace
58
Marshall Wace
United Kingdom
-$245K -24,451 Closed
MWNA
59
Marshall Wace North America
New York
-$71K -7,087 Closed
Victory Capital Management
60
Victory Capital Management
Texas
-$35K -3,454 Closed

XERS Hedge Fund Activity: Q2 2019 in Review

50 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Xeris Biopharma Holdings (XERS) for Q2 2019, worth a combined $193M — up 20% from $161M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new XERS positions and 10 closed out — a net gain of 3 holders — while 21 added to existing stakes and 8 trimmed.

The largest buyer was Invesco, opening a new position worth an estimated $10.5M. The largest seller was Millennium Management, exiting entirely with an estimated $1.21M sold.

  • 50 institutional investors held Xeris Biopharma Holdings (XERS) as of Q2 2019, up from 49 in Q1 2019.
  • Funds reported $193M of Xeris Biopharma Holdings stock for Q2 2019, up 20% quarter-over-quarter.
  • 13 funds opened new Xeris Biopharma Holdings positions in Q2 2019 and 10 closed out, a net change of +3 holders.
  • The largest Xeris Biopharma Holdings buyer in Q2 2019 was Invesco, an estimated $10.5M added.
  • The largest Xeris Biopharma Holdings seller in Q2 2019 was Millennium Management, an estimated $1.21M sold.

Based on aggregated 13F filings for Q2 2019.